0001193125-21-300050.txt : 20211015 0001193125-21-300050.hdr.sgml : 20211015 20211015161901 ACCESSION NUMBER: 0001193125-21-300050 CONFORMED SUBMISSION TYPE: 15-12B PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20211015 DATE AS OF CHANGE: 20211015 EFFECTIVENESS DATE: 20211015 FILER: COMPANY DATA: COMPANY CONFORMED NAME: XERIS PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001346302 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 203352427 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 15-12B SEC ACT: 1934 Act SEC FILE NUMBER: 001-38536 FILM NUMBER: 211326276 BUSINESS ADDRESS: STREET 1: 180 NORTH LASALLE STREET STREET 2: SUITE 1600 CITY: CHICAGO STATE: IL ZIP: 60601 BUSINESS PHONE: 844-445-5704 MAIL ADDRESS: STREET 1: 180 NORTH LASALLE STREET STREET 2: SUITE 1600 CITY: CHICAGO STATE: IL ZIP: 60601 15-12B 1 d235902d1512b.htm 15-12B 15-12B

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 15

 

 

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION

UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number 001-38536

 

 

XERIS PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

 

180 N. LaSalle Street, Suite 1600

Chicago, Illinois 60601

(844) 445-5704

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

COMMON STOCK, PAR VALUE $0.0001 PER SHARE

(Title of each class of securities covered by this Form)

NONE

(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

 

 

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

 

Rule 12g-4(a)(1)

    ☒  

Rule 12g-4(a)(2)

    ☐  

Rule 12h-3(b)(1)(i)

    ☒  

Rule 12h-3(b)(1)(ii)

    ☐  

Rule 15d-6

    ☐  

Rule 15d-22(b)

    ☐  

Approximate number of holders of record as of the certification or notice date: 1

 

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, Xeris Pharmaceuticals, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

 

DATE: October 15, 2021     BY:  

/s/ Steven M. Pieper

      Steven M. Pieper
      Chief Financial Officer